| abstract |
The present invention has an attenuated phenotype and includes one or more mutations in the viral P, M2-1, and / or M2-2 proteins, as well as nucleic acids encoding such viruses and such viruses. A recombinant respiratory syncytial virus comprising a live attenuated vaccine is provided. Recombinant RSVP, M2-1, and M2-2 proteins have been described. Also provided are methods of producing attenuated recombinant RSV and methods of quantifying neutralizing antibodies that utilize Paramyxoviridae recombinant viruses. |